KAHR, a clinical-stage biotech company developing DSP107, a first-in-class bi-specific 4-1BB T-cell engager that activates innate and adaptive immunity to treat solid tumors, today announced that positive results from the Phase 2 dose expansion cohort of DSP107 in combination with atezolizumab (Tecentriq®), an anti-PD-L1 cancer immunotherapy, in patients with 3rd line microsatellite stable metastatic colorectal cancer (MSS-CRC) will be presented in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will be held May 30 – June 3, 2025, in Chicago, Illinois and virtually. In addition to its favorable safety profile, the combination has shown anti-tumor activity and extended survival including in patients with liver metastases.
“We are happy with the opportunity to present data from the Phase 2 dose expansion cohort of DSP107 in combination with a PD1/PD-L1 checkpoint inhibitor in an oral presentation at ASCO’s Annual Meeting,” said Yaron Pereg, Ph.D., Chief Executive Officer of KAHR. “This recognition is evidence for the significant potential of this immunotherapy combination to benefit the treatment of MSS-CRC patients including those with active liver metastases, a devastating disease representing an unmet medical need. We look forward to sharing next week the exciting, updated, overall survival data for this combination, which has continued to improve in 2025 beyond the data published in the abstract.”
